2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2645

The Anteromedial Ultrasound Examination of the Large Supraaortic Vessels Identifies Higher Rates of Large Vessel Involvement Than Previous Reported in Patients with Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2425

The anti-Ro52 Prevalence in the Sjögren’s Syndrome Picture: A Single Center Cross Sectional Study

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2657

The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2323

The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2501

The Association Between Metabolic Syndrome and Radiographic Damage in Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2267

The Association Between Non-restorative Sleep and Diurnal Patterns of Cognitive Function and Fatigue in People with Fibromyalgia and Matched Controls

Psychology/Social Science Poster – ARP

9:00AM-11:00AM: Abstract Number: 2188

The Association of Plasma Fatty Acids Levels with Hand and Knee Osteoarthritis

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 2073

The Association of Serum Uric Acid Levels and the Risk of Lower Urinary Tract Symptoms in Korean Healthy Adults

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2703

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2105

The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2596

The Contribution of Left Heart Disease in Patients with Systemic Sclerosis-associated Pulmonary Hypertension Having Normal Pulmonary Artery Wedge Pressure

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2299

The Course of Disability in Early Rheumatoid Arthritis over 10 Years of Follow-up in Women and Men – Comparison with the General Population

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2638

The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2060

The Current State of Big Data Use and Artificial Intelligence in RMDs: A Systematic Literature Review Informing EULAR Recommendations

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2490

The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].